207 related articles for article (PubMed ID: 36525619)
1. Benefits of Adopting Hypofractionated Radiotherapy as a Standard of Care in Low-and Middle-Income Countries.
Kraus RD; Weil CR; Abdel-Wahab M
JCO Glob Oncol; 2022 Dec; 8():e2200215. PubMed ID: 36525619
[No Abstract] [Full Text] [Related]
2. Practical considerations for prostate hypofractionation in the developing world.
Yan M; Gouveia AG; Cury FL; Moideen N; Bratti VF; Patrocinio H; Berlin A; Mendez LC; Moraes FY
Nat Rev Urol; 2021 Nov; 18(11):669-685. PubMed ID: 34389825
[TBL] [Abstract][Full Text] [Related]
3. Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy.
Irabor OC; Swanson W; Shaukat F; Wirtz J; Mallum AA; Ngoma T; Elzawawy A; Nguyen P; Incrocci L; Ngwa W
JCO Glob Oncol; 2020 Apr; 6():667-678. PubMed ID: 32343628
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil.
Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA
Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478
[TBL] [Abstract][Full Text] [Related]
5. [Moderate hypofractionated radiotherapy for bladder cancer-a new standard of care?].
Ott OJ
Strahlenther Onkol; 2021 Sep; 197(9):854-856. PubMed ID: 34228169
[No Abstract] [Full Text] [Related]
6. Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward.
Krug D; Baumann R; Combs SE; Duma MN; Dunst J; Feyer P; Fietkau R; Haase W; Harms W; Hehr T; Piroth MD; Sedlmayer F; Souchon R; Strnad V; Budach W;
Strahlenther Onkol; 2021 Apr; 197(4):269-280. PubMed ID: 33507331
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer: Moderate hypofractionated radiotherapy - not yet a standard of care.
Pollack A; Abramowitz M
Nat Rev Clin Oncol; 2016 Nov; 13(11):655-656. PubMed ID: 27644320
[No Abstract] [Full Text] [Related]
8. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
9. Hypofractionation in Breast Cancer Radiotherapy Across World Bank Income Groups: Results of an International Survey.
Mushonga M; Weiss J; Liu ZA; Nyakabau AM; Mohamad O; Tawk B; Moraes FY; Grover S; Yap ML; Zubizarreta E; Lievens Y; Rodin D
JCO Glob Oncol; 2023 Jan; 9():e2200127. PubMed ID: 36706350
[TBL] [Abstract][Full Text] [Related]
10. Hematological Toxicity of Hypofractionated Radiotherapy: A Review of the Available Evidence.
Spałek M; Wyrwicz L
Oncol Res Treat; 2018; 41(11):713-718. PubMed ID: 30317235
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy in the real-world setting: An international ESTRO-GIRO survey.
Rodin D; Tawk B; Mohamad O; Grover S; Moraes FY; Yap ML; Zubizarreta E; Lievens Y
Radiother Oncol; 2021 Apr; 157():32-39. PubMed ID: 33453312
[TBL] [Abstract][Full Text] [Related]
12. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
13. Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).
Shelan M; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Müller AC; Niehoff P; Pinkawa M; Schmidt-Hegemann NS; Sedlmayer F; Wolf F; Zamboglou C; Zips D; Wiegel T; Ghadjar P
Strahlenther Onkol; 2021 Nov; 197(11):993-1000. PubMed ID: 34463814
[TBL] [Abstract][Full Text] [Related]
14. Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database.
Kang MM; Hasan Y; Waller J; Saulsberry L; Huo D
Clin Breast Cancer; 2022 Jan; 22(1):e8-e20. PubMed ID: 34257001
[TBL] [Abstract][Full Text] [Related]
15. Trends and Patterns of Utilization of Hypofractionated Postmastectomy Radiotherapy: A National Cancer Database Analysis.
Venigalla S; Guttmann DM; Jain V; Sharma S; Freedman GM; Shabason JE
Clin Breast Cancer; 2018 Oct; 18(5):e899-e908. PubMed ID: 29550285
[TBL] [Abstract][Full Text] [Related]
16. The Evolving Role of Hypofractionated Radiotherapy in Older Adults with Gastrointestinal Cancers.
Zhang-Velten E; Sanford NN
Semin Radiat Oncol; 2022 Apr; 32(2):159-167. PubMed ID: 35307118
[TBL] [Abstract][Full Text] [Related]
17. Moderate Hypofractionated Radiotherapy for Localized Prostate Cancer: The Triumph of Radiobiology.
Kougioumtzopoulou A; Platoni K; Zygogianni A; Kounadis G; Syrigos KN; Psyrri A; Bamias A; Kelekis N; Kouloulias V
Rev Recent Clin Trials; 2021; 16(4):351-371. PubMed ID: 33966623
[TBL] [Abstract][Full Text] [Related]
18. Is hypofractionation acceptable for prostate bed radiotherapy?
López Campos F; Sancho Pardo G; Maldonado Pijoan X; Zilli T; Couñago Lorenzo F; Hervás Morón A
Urol Oncol; 2021 Jun; 39(6):346-350. PubMed ID: 34049781
[TBL] [Abstract][Full Text] [Related]
19. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
